Close Menu

NEW YORK – Adaptive Biotechnologies today announced a partnership with AbbVie to use next-generation sequencing-based minimal residual disease testing in multiple myeloma drug trials.

Under the terms of the multi-year, global collaboration agreement, AbbVie will use Adaptive's clonoSeq assay to assess MRD status in response to venetoclax across multiple clinical trials. The partners will evaluate the depth and duration of response to venetoclax by using clonoSeq to measure and monitor MRD negativity in treated patients.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Undark looks into how coronavirus-related shutdowns are affecting field researchers.

In PNAS this week: strategies to design DNA oligonucleotide probes for bacteria, Vibrio cholerae evolution in Haiti, and more.

NPR reports that graduate students in the US are helping with SARS-CoV-2 testing.

Politico reports President Donald Trump has signed the $2 trillion coronavirus relief package.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.